Sorry, guys, but remember the number one rule of stocks: Don't fall in love with your stock. We have been generous on this thread at giving Lidak multiple benefits of the doubt.
Michael: The trial comparing Lidakol with Zovirax (acyclovir) does not sound too exciting to me. We all know that acyclovir (or similar compounds), whether in oral or topical form, is pretty much the only approved treatment for herpes currently. We also know that it is not very effective at all, as acyclovir is just a hair better than untreated.
(1) Thus, we can assert that Zovirax ointment is marginally beneficial
(2) The story then says that Zovirax cream is not as efficacious as the ointment.
(3) The story than says that Lidakol is comparable to Zovirax cream.
Unless I'm misinterpreting it, Lidakol is, at best, a marginally effective agent. It may be true that "Lidakol was as effective as the best treatment available," - but the best treatment available is pretty lousy, as we all know!! This statement is yet another example of Lidak misleading investors, without actually lying. Multiple misleading statements like this is what turned me away from this company.
Also, Henry, it is probably incorrect to assert that Bristol Myers is not interested in Lidakol because it may be an over the counter preparation. Bristol Myers, like all pharmaceutical companies, has tons of non prescription, over-the-counter products, like Excedrin, Bufferin, Nuprin, Keri Lotion, Ban deodorant, and the Clairol line. They would salivate at any product that could ease cold sore and herpetic sore pain. To continue their almost exclusive relationship with Lidakol would cost Bristol Myers almost nothing. Yet they walked away and allowed all their competitors a free shot at lidakol. Why?
Here is a listing of BMS consumer products
bms.com |
